In one paragraphArticle in Oncoimmunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Jesper van Eck van der SluijsDepartment of Radiation Oncology, Laboratory of Radiotherapy & OncoImmunology, Radboud Institute for Medical Innovation, Radboudumc, Nijmegen, the Netherlands.ORCID 0000-0003-3136-7799 Anne H C ValkDepartment of Radiation Oncology, Laboratory of Radiotherapy & OncoImmunology, Radboud Institute for Medical Innovation, Radboudumc, Nijmegen, the Netherlands.ORCID 0000-0002-6190-0438 Eline J H van HoutumDepartment of Radiation Oncology, Laboratory of Radiotherapy & OncoImmunology, Radboud Institute for Medical Innovation, Radboudumc, Nijmegen, the Netherlands.ORCID 0000-0001-9037-4388 Esther D Kers-RebelDepartment of Radiation Oncology, Laboratory of Radiotherapy & OncoImmunology, Radboud Institute for Medical Innovation, Radboudumc, Nijmegen, the Netherlands.
Maaike LoomanDepartment of Radiation Oncology, Laboratory of Radiotherapy & OncoImmunology, Radboud Institute for Medical Innovation, Radboudumc, Nijmegen, the Netherlands.
Willemijn HoboDepartment of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Medical Innovation, Radboudumc, Nijmegen, the Netherlands.
Anna E MarnethDepartment of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Medical Innovation, Radboudumc, Nijmegen, the Netherlands.ORCID 0000-0001-9065-0581 Harry DolstraDepartment of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Medical Innovation, Radboudumc, Nijmegen, the Netherlands.ORCID 0000-0002-3998-687X Lune van den BoogaardDepartment of Radiation Oncology, Laboratory of Radiotherapy & OncoImmunology, Radboud Institute for Medical Innovation, Radboudumc, Nijmegen, the Netherlands.ORCID 0009-0004-9060-2925 Christian BüllDepartment of Biomolecular Chemistry, Institute for Molecules and Materials, Radboud University, Nijmegen, the Netherlands.ORCID 0000-0001-7785-2920 Lenneke A M CornelissenDepartment of Radiation Oncology, Laboratory of Radiotherapy & OncoImmunology, Radboud Institute for Medical Innovation, Radboudumc, Nijmegen, the Netherlands.ORCID 0000-0003-2210-1606 Gosse J AdemaDepartment of Radiation Oncology, Laboratory of Radiotherapy & OncoImmunology, Radboud Institute for Medical Innovation, Radboudumc, Nijmegen, the Netherlands.ORCID 0000-0002-6750-1665 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
The glyco-immune checkpoints Siglec-7 and Siglec-9 have received considerable interest as targets for cancer immunotherapy. How Siglec-7/9-sialic acid
Indexed as
Antigens, CDAntigens, Differentiation, B-LymphocyteAntigens, Differentiation, MyelomonocyticKiller Cells, NaturalLectinsMelanomaN-Acetylneuraminic AcidSialic Acid Binding Immunoglobulin-like LectinsCell Line, TumorHumansJurkat CellsLeukemia, Myeloid, AcuteLigandsSignal TransductionTetraspanin 29Antigens, CDAntigens, Differentiation, B-LymphocyteAntigens, Differentiation, MyelomonocyticCD9 protein, humanLectinsLigandsN-Acetylneuraminic AcidSialic Acid Binding Immunoglobulin-like LectinsSIGLEC7 protein, humanSIGLEC9 protein, humanTetraspanin 29acute myeloid leukemiaanti-tumor immunitycis-ligand, sialic acidimmune checkpointimmunotherapymelanomanatural killer cellsSiglec-7Siglec-9
Identifiers
PMID41928453
PMCPMC13051614
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390